← FDA DRUG APPROVALS

FDA NDA · NDA022202

ZIPSOR

diclofenac potassium

Sponsor: COSETTE

APPLICATION
NDA022202
TYPE
NDA
ORIGINAL APPROVAL
2009-06-16
LATEST ACTION
2024-11-21
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

ZIPSOR · ReferencePrescription
DICLOFENAC POTASSIUM 25MG · CAPSULE · ORAL

Approval history

2024-11-21Labeling · Supplement 16 · standardLetterAP
2021-05-25Labeling · Supplement 14 · standardLetterAP
2021-05-25Efficacy · Supplement 13 · standardLetterAP
2016-05-09Labeling · Supplement 11 · standardLabelAP
2015-12-16Labeling · Supplement 10 · standardAP
2015-08-07Manufacturing (CMC) · Supplement 8 · standardAP
2011-05-04REMS · Supplement 3LetterAP
2011-05-04REMS · Supplement 4LetterAP
2009-06-16Type 3 - New Dosage Form · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →